XW023X7
Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
Historical code
This code is not active in the current release.
Last release it was active in: FY 2026
Effective –
- Release
- FY 2026
- Effective
Character Breakdown
Each character position in XW023X7 resolves to one value from the official ICD-10-PCS tables.
- 1. Section X — New Technology
- 2. Body System W — Anatomical Regions
- 3. Operation 0 — Introduction
- 4. Body Part 2 — Muscle
- 5. Approach 3 — Percutaneous
- 7. Qualifier 7 — New Technology Group 7
- 0 · Operation: Introduction
- Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Hierarchy
Where XW023X7 sits in the official hierarchy. Each level is the code it is classified under.
- XW0 Parent New Technology, Anatomical Regions, Introduction
- XW023X7 This code Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
Version History
How XW023X7 appears in each release imported from the official files, newest first.
-
FY 2027 Effective
DeletedLast description Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
-
FY 2026 Effective
UnchangedIntroduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
Related Codes
Other codes under XW0
- XW00X27 Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7 Billable
- XW01318 Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 Billable
- XW01329 Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 Billable
- XW01348 Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 Billable
- XW0136A Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10 Billable
- XW01397 Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 Billable
- XW013F5 Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 Billable
- XW013G6 Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Billable
- XW013H6 Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Billable
- XW013K6 Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Billable
- XW013L9 Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 Billable
- XW013S6 Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Billable
- XW013S9 Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 Billable
- XW013T6 Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Billable
- XW013TB Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11 Billable
- XW013U6 Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Billable
- XW013V7 Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 Billable
- XW013W5 Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 Billable
- XW013W7 Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 Billable
- XW01X27 Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7 Billable
- XW020D8 Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8 Billable
- XW023S6 Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6 Billable
- XW023T6 Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6 Billable
- XW023U6 Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6 Billable
Data Source
Code information on this page is derived from the FY 2026 ICD-10-PCS files published by CMS.
- Release
- FY 2026
- Effective
- –
- Source file
- 2026-icd-10-pcs-order-file-long-and-abbreviated-titles.zip
Official ICD-10-PCS source files (opens in a new tab)
MedCodeSearch is an independent reference service and is not affiliated with CMS, CDC, or the U.S. government.
Look up another code
Search ICD-10-CM, ICD-10-PCS and HCPCS Level II by code or description.